Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097799
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2016-11-30
First Post:
2004-11-30
Brief Title:
Tipranavir Expanded Access Program EAP in PI-experienced Patients With HIV-1 Infection
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
An Open Label Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir TPVr in Protease Inhibitor-experienced Patients With HIV-1 Infection the Tipranavir Expanded Access Program
Status:
APPROVED_FOR_MARKETING
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to provide early access to and evaluate the safety of TPVr in PI-experienced patients with HIV-1 infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: